David L Schlotterbeck

Title: David L Schlotterbeck: Innovator in Cancer Treatment

Introduction

David L Schlotterbeck is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of cancer treatment through his innovative approaches. His work focuses on enhancing the efficacy of checkpoint inhibitors, which are crucial in cancer immunotherapy.

Latest Patents

David L Schlotterbeck holds a patent titled "Increasing responses to checkpoint inhibitors by extracorporeal apheresis." This invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. Specifically, it teaches the utilization of extracorporeal apheresis to remove various tumor-derived or tumor microenvironment-derived immunological 'blocking factors.' One embodiment of the invention involves the removal of soluble TNF-alpha receptors (sTNF-Rs) to augment the efficacy of immune checkpoint inhibitors. This method is particularly effective in enhancing the efficacy of inhibitors targeting the PD-1/PD-L1 pathway and the CD28/CTLA-4 pathway. He has 1 patent to his name.

Career Highlights

David L Schlotterbeck is associated with Immunicom, Inc., where he continues to develop innovative solutions for cancer treatment. His work has been instrumental in advancing the understanding of how to improve patient responses to existing therapies.

Collaborations

David has collaborated with notable professionals in the field, including Thomas Emanuel Ichim and Steven Francis Josephs. These collaborations have further enriched his research and development efforts.

Conclusion

David L Schlotterbeck is a key figure in the innovation of cancer therapies, particularly through his patent on enhancing checkpoint inhibitor responses. His contributions are paving the way for more effective cancer treatments.